- Home
- AHG vs NRIX Comparison
AHG vs NRIX Comparison
Compare AHG & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AHG | NRIX |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AHG | NRIX |
|---|---|---|
| Price | $1.53 | $17.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $30.50 |
| AVG Volume (30 Days) | 14.3K | ★ 843.5K |
| Earning Date | 08-14-2025 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $76,987,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $48.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $1.08 | $8.20 |
| 52 Week High | $2.50 | $22.50 |
Technical Indicators
Market Signals| Indicator | AHG | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 28.14 | 60.00 |
| Support Level | $1.28 | $17.21 |
| Resistance Level | $1.73 | $19.98 |
| Average True Range (ATR) | 0.18 | 0.83 |
| MACD | -0.07 | 0.08 |
| Stochastic Oscillator | 1.43 | 83.09 |
Price Performance
Historical ComparisonAbout AHG Akso Health Group ADS
Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.